BMS-641988
Experimental drug for prostate cancer
{{Drugbox
| verifiedfields = changed
| verifiedrevid = 477002123
| IUPAC_name = (2S)-N-[(1R)-1-Cyano-2-phenylethyl]-3-(4-cyanophenyl)-2-[[4-(trifluoromethyl)phenyl]methylamino]propanamide
| image = BMS-641988_structure.png
| width = 250
| CAS_number = 1001350-96-4
| PubChem = 16054624
| ChemSpiderID = 17286447
| UNII = 9X0X8R0X0Q
| KEGG = D09992
| ChEMBL = 2103874
| C=28
| H=24
| F=3
| N=3
| O=1
| smiles = C1=CC=C(C=C1)C(C#N)C(C(=O)NC(C2=CC=C(C=C2)C#N)CNC3=CC=C(C=C3)C(F)(F)F)N
}}
BMS-641988 is an investigational drug developed by Bristol-Myers Squibb for the treatment of prostate cancer. It is a nonsteroidal antiandrogen that acts as an antagonist of the androgen receptor.
Mechanism of Action
BMS-641988 functions by inhibiting the activity of the androgen receptor, a critical driver of prostate cancer cell growth. By blocking this receptor, BMS-641988 prevents the binding of androgens, such as testosterone and dihydrotestosterone, which are necessary for the proliferation of prostate cancer cells.
Development and Clinical Trials
BMS-641988 was developed as part of a series of compounds aimed at improving the treatment of castration-resistant prostate cancer (CRPC). Preclinical studies demonstrated its potential efficacy in inhibiting tumor growth. However, during clinical trials, concerns about its safety profile, particularly regarding seizure risk, led to the discontinuation of its development.
Pharmacokinetics
The pharmacokinetic profile of BMS-641988 includes its absorption, distribution, metabolism, and excretion characteristics. It was designed to have a favorable oral bioavailability and a half-life suitable for once-daily dosing. The drug undergoes hepatic metabolism, primarily via the cytochrome P450 enzyme system.
Safety and Efficacy
While BMS-641988 showed promise in preclinical models, its clinical development was halted due to adverse effects observed in early-phase trials. The primary concern was the occurrence of seizures, which posed significant safety risks to patients.
Related Pages
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD